ASTERIX: low dose ASA and Nexium
Study identifier:D9617C00011
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A randomized double-blind placebo-controlled study to assess the prevention of low-dose acetylsalicylic acid (ASA) associated gastroduodenal lesions and upper gastrointestinal symptoms in patients taking esomeprazole 20 mg once daily for 26 weeks.
Medical condition
Gastroesophageal Reflux
Phase
Phase 3
Healthy volunteers
No
Study drug
Esomeprazole
Sex
All
Actual Enrollment
960
Study type
Interventional
Age
60 Years - 100 Years
Date
Study Start Date: 01 May 2004
Primary Completion Date: -
Study Completion Date: 01 Sept 2005
Study design
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Prevention
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Contact
AstraZeneca Clinical Study Information
-
-
Investigators
Principal Investigator
AstraZeneca Nexium Medical Science Director
AstraZeneca
